Sodium hydrogen carbonate (Thamicarb®)

Assessment Status Rapid review complete
HTA ID 20043
Drug Sodium hydrogen carbonate
Brand Thamicarb®
Indication For metabolic acidosis in chronic kidney disease.
Assessment Process
Rapid review commissioned 28/09/2020
Rapid review completed 23/11/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that sodium hydrogen carbonate (Thamicarb®) not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.